Published in Stroke on May 13, 2014
Interventional Management of Stroke (IMS) III Trial (IMSIII) | NCT00359424
Impact of General Anesthesia on Safety and Outcomes in the Endovascular Arm of Interventional Management of Stroke (IMS) III Trial. Stroke (2015) 1.43
Mechanical Thrombectomy in Patients With Acute Ischemic Stroke: A Health Technology Assessment. Ont Health Technol Assess Ser (2016) 0.77
Mechanical thrombectomy in patients with acute ischemic stroke: a cost-utility analysis. CMAJ Open (2016) 0.75
The Effect of Diagnostic Catheter Angiography on Outcomes of Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment. J Vasc Interv Neurol (2017) 0.75
Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III. J Am Heart Assoc (2017) 0.75
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med (2013) 14.78
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92
Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology (1998) 3.62
Anesthetic management and outcome in patients during endovascular therapy for acute stroke. Anesthesiology (2012) 3.02
Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology (2012) 2.91
Comparison of 30-day mortality models for profiling hospital performance in acute ischemic stroke with vs without adjustment for stroke severity. JAMA (2012) 2.38
A cost-utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke. Stroke (2011) 1.72
An investigation of the cost and benefit of mechanical thrombectomy for endovascular treatment of acute ischemic stroke. J Neurointerv Surg (2013) 1.07
Impact of disability status on ischemic stroke costs in Canada in the first year. Can J Neurol Sci (2012) 1.01
Hospitalization costs for acute ischemic stroke patients treated with intravenous thrombolysis in the United States are substantially higher than medicare payments. Stroke (2011) 0.96
Cost-effectiveness of CT perfusion for selecting patients for intravenous thrombolysis: a US hospital perspective. AJNR Am J Neuroradiol (2010) 0.88
Design of the economic evaluation for the Interventional Management of Stroke (III) trial. Int J Stroke (2008) 0.84
The cost-effectiveness of primary stroke centers for acute stroke care. Stroke (2012) 0.84
Hospitalization resource use and costs before and after TIA and stroke: results from a population-based cohort study (OXVASC). Value Health (2013) 0.83
Cost avoidance associated with optimal stroke care in Canada. Stroke (2012) 0.83
Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. Radiology (2014) 1.46
Collaterals at angiography and outcomes in the Interventional Management of Stroke (IMS) III trial. Stroke (2014) 1.38
Increasing use of CT angiography in interventional study sites: the IMS III experience. AJNR Am J Neuroradiol (2010) 1.20
Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. Stroke (2014) 0.86
Outcome Differences between Intra-Arterial Iso- and Low-Osmolality Iodinated Radiographic Contrast Media in the Interventional Management of Stroke III Trial. AJNR Am J Neuroradiol (2015) 0.75
Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions. J Neurointerv Surg (2014) 0.75
Endovascular Therapy of M2 Occlusion in IMS III: Role of M2 Segment Definition and Location on Clinical and Revascularization Outcomes. AJNR Am J Neuroradiol (2016) 0.75